Evidence map›Paper›PMID 18810543›Full record

ArticleCurrent microbiology2008

Identification of a potential lead structure for designing new antimicrobials to treat infections caused by Staphylococcus epidermidis-resistant strains.

Luiz C S Pinheiro, Paula A Abreu, Ilidio F Afonso, Bruno Leal, Luiz C D Corrêa, Júlio C Borges, Isakelly P Marques, André L Lourenço, Plinio Sathler, Andre L dos Santos and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Current microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. β-Ketoamides in Thieno[2,3-Molecules (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. N-(4-Chloro-phen-yl)-5-(4,5-dihydro-1H-imidazol-2-yl)thieno[2,3-b]pyridin-4-amine.Acta crystallographica. Section E, Structure reports online · 2012
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Luiz C S PinheiroInstituto de Química, Departamento de Química Orgânica, Programa de Pós-Graduação em Química Orgânica, Universidade Federal Fluminense, Campus do Valonguinho, CEP 24020-150, Niteroi, RJ, Brazil.
Paula A Abreu
Ilidio F Afonso
Bruno Leal
Luiz C D Corrêa
Júlio C Borges
Isakelly P Marques
André L Lourenço
Plinio Sathler
Andre L dos Santos
Cid A Medeiros
Lúcio M Cabral
Maurício L O Júnior
Gilberto A Romeiro
Vitor F Ferreira
Carlos R Rodrigues
Helena C Castro
Alice M R Bernardino

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacterial infections are a significant cause of morbidity and mortality among critically ill patients. The increase of antibiotic resistance in bacteria from human microbiota-such as Staphylococcus epidermidis, an important nosocomial pathogen that affects immunocompromised patients or those with indwelling devices-increased the desire for new antibiotics. In this study we designed, synthesized, and determined the antimicrobial activity of 27 thieno[2,3-b]pyridines (1, 2, 2a-2m, 3, 3a-3m) derivatives against a drug-resistant clinical S. epidermidis strain. In addition, we performed a structure-activity relationship analysis using a molecular modeling approach, and discuss the drug absorption, distribution, metabolism, excretion, and toxicity profile and Lipinski's "rule of five," which are tools to assess the relationship between structures and drug-like properties of active compounds. Our results showed that compound 3b (5-(1H-tetrazol-5-yl)-4-(3;-methylphenylamino)thieno[2,3-b]pyridine) was as active as oxacillin and chloramphenicol but with lower theoretical toxicity risks and a better drug likeness and drug score potential than chloramphenicol. All molecular modeling and biological results reinforced the promising profile of 3b for further experimental investigation and development of new antibacterial drugs.

Indexed as

Drug DesignDrug Resistance, BacterialAnti-Bacterial AgentsBacteriaDrug Evaluation, PreclinicalHumansMicrobial Sensitivity TestsModels, MolecularPyridinesStaphylococcal InfectionsStaphylococcus epidermidisStructure-Activity RelationshipAnti-Bacterial AgentsPyridines

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.